根据联交所获得的证据，王先生（该公司当时的借贷业务负责人）前后批准该公司授出及/或延长八笔 涉及本金金额合共1.383亿港元的贷款，事前却没有进行足够的尽职审查、风险分析及信贷评估，亦未 有妥善评估及监察相关抵押资产是否充足。部分贷款人为王先生家人，但无证据显示王先生有就此申 报。该公司2019年全年业绩中就应收贷款作出了约86%的减值。 王先生及田女士亦被发现曾于2018年该公司出售若干附属公司时，促使该公司在无担保及免息的基础上 允许将买方支付代价9300万元人民币的限期押后到出售事项完成后数月。买方最后并未支付任何代价， 导致该公司2019年全年业绩录得9300万元人民币的全额减值。概无证据显示王先生或田女士于出售事项 前有对买方进行任何尽职审查或信贷评估。 智通财经APP获悉，5月28日，香港联合交易所有限公司宣布对中国健康科技集团控股有限公司(01069) （前称中国宝沙发展控股有限公司）两名前董事王岳和田光梅作出纪律处分。联交所认为二人不适合担 任公司或其附属公司的董事或高级管理职务，原因是他们在2015年至2019年从事公司借贷业务及2018年 促使公司出售附属公司时，未履行董事职责，且未配合联 ...

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 及 前 稱 為 （股份代號：1069） China Bozza Development Holdings Limited 中 國 寶 沙 發 展 控 股 有 限 公 司 ） 2024 中 期 報 告 (Incorporated in the Cayman Islands with limited liability and formerly known as (Stock code: 1069) China Bozza Development Holdings Limited 中 國 寶 沙 發 展 控 股 有 限 公 司 ) 2024 INTERIM REPORT 目 錄 2 公司資料 4 管理層討論及分析 11 其他資料及公司管治 15 簡明綜合損益及其他全面收益表 16 簡明綜合財務狀況表 18 簡明綜合權益變動表 19 簡明綜合現金流量表 20 簡明綜合中期財務報表附註 公司資料 董事 執行董事 凌鋒教授 （主席） 王義斌先生 獨立非執行董事 郭中隆先生 周穎楠先生 畢雪女士 審核委員會 周穎楠先生 （主席） 郭中隆先生 畢雪女士 薪酬委員會 ...

Financial Performance - The company's revenue for the six months ended December 31, 2024, was RMB 31,112,000, representing a 63.5% increase compared to RMB 19,020,000 for the same period in 2023[4] - Gross profit for the same period was RMB 2,777,000, down 26.2% from RMB 3,758,000 in the previous year[4] - The company reported a pre-tax profit of RMB 5,042,000, a significant decrease from RMB 201,423,000 in the prior period, largely due to a one-time debt restructuring gain in the previous year[4] - The net profit for the six months was RMB 4,978,000, compared to RMB 201,421,000 in the previous year[4] - Total comprehensive income for the period was RMB 6,353,000, down from RMB 207,869,000 in the same period last year[4] - The net profit for the six months ended December 31, 2024, was RMB 4,978,000, compared to RMB 201,421,000 for the same period in 2023, showing a significant decrease due to restructuring costs[19][24] - The company recorded a debt restructuring gain of approximately RMB 202,024,000 during the review period, significantly impacting the financial results[24] - The financing costs for the six months ended December 31, 2024, were RMB 1,337,000, a notable increase from RMB 51,000 in the previous period[22] - The company reported a profit of approximately RMB 5,000,000, a significant decrease from RMB 201,400,000 in the previous period[49] Assets and Liabilities - The company's non-current assets totaled RMB 137,728,000 as of December 31, 2024, an increase from RMB 130,844,000 as of June 30, 2024[5] - Current assets increased to RMB 53,357,000 from RMB 47,322,000 in the previous period[5] - The company's total liabilities were RMB 53,356,000, compared to RMB 49,315,000 in the previous period, indicating a rise in financial obligations[6] - The total assets as of December 31, 2024, amounted to RMB 191,085,000, up from RMB 178,166,000 as of June 30, 2024, reflecting a growth of 7.1%[20] - The total liabilities increased to RMB 171,826,000 from RMB 165,203,000, indicating a rise of 4.0%[20] - As of December 31, 2024, the company had total assets of approximately RMB 191,100,000 and net assets of approximately RMB 24,900,000[50] - The capital debt ratio was approximately 87.0%, improved from 92.7% as of June 30, 2024[54] Business Segments - The company is engaged in forestry management, ginseng cultivation and trade, and health product manufacturing, indicating a diversified business model[8] - The forestry business generated revenue of RMB 11,564,000, while the ginseng business contributed RMB 16,152,000, indicating strong performance in these segments[19] - The health products segment generated revenue of RMB 3,396,000, contributing positively to the overall performance[19] - The company achieved a total revenue of approximately RMB 11,560,000 from timber sales during the reporting period, with a total harvesting volume of 8,547 cubic meters[36] - Ginseng business revenue reached approximately RMB 16,150,000, which includes RMB 10,770,000 from purchased ginseng and RMB 5,380,000 from self-cultivated ginseng[39] - The health products segment generated revenue of approximately RMB 3,400,000 since its launch in November 2024[40] - The company has initiated a health product manufacturing and trading business, with plans to produce ginseng gift boxes using self-cultivated ginseng by the first half of 2025[40] - The company has secured a harvesting permit for 2024, allowing for the planned timber sales to continue[36] - The company has established a long-term supply framework agreement with suppliers to ensure a stable supply of ginseng for its trading business[39] Governance and Compliance - The company has adopted all provisions of the corporate governance code as per the listing rules, ensuring compliance throughout the reporting period[68] - The board confirmed that all directors adhered to the code of conduct for securities trading during the reporting period[69] - The company has not purchased any liability insurance for directors and executives against legal claims as of December 31, 2024[70] - The audit committee, consisting of three independent non-executive directors, focuses on compliance with accounting standards and legal regulations[71] - The unaudited interim financial statements have been reviewed by the audit committee during the reporting period[72] - The interim results announcement will be published on the Hong Kong Stock Exchange and the company's website, containing all required information[73] - The board includes both executive and independent non-executive directors, ensuring a diverse governance structure[75] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] - The company successfully planted its first batch of Epimedium on its owned forest land in June 2024, which is expected to generate revenue in the future[42]

B CHINA HEALTH China Health Technology Group Holding Company Limited 中國健康科技集團控股有限公司 (於開曼群島註冊成立的有限公司及前稱為 China Bozza Development Holdings Limited 中國資沙發展控股有限公司) (股份代號：1069) 年 報 目 錄 | --- | --- | |--------------------------|-------| | | | | 公司資料 | 2 | | 財務概要 | 4 | | 管理層討論及分析 | 5 | | 董事及高級管理層履歷資料 | 16 | | 董事會報告 | 18 | | 企業管治報告 | 25 | | 獨立核數師報告 | 37 | | 綜合損益及其他全面收益表 | 44 | | 綜合財務狀況表 | 45 | | 綜合權益變動表 | 47 | | 綜合現金流量表 | 48 | | 綜合財務報表附註 | 50 | 公司資料 公司資料 董 事 | --- | --- | |-----------------------|----------| | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1069） 截至二零二四年六月三十日止年度之財務業績公告 | --- | --- | |-------|------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 財務摘要 | | • | 截至二零二四年六月三十日止年度（「 二零二四財年 」）之收益約為人民幣 （「 人民幣 」） 47,600,000 元。 | | • | 於二零二四財年，本公司擁有人應佔溢利約為人民幣 200,000,000 元（截至二 零二三年六月三十日止年度（「 二零二三財年 」）：虧損約人民幣 10,800,000 元）。 | ...

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 及 前 稱 為 （股份代號：1069） China Bozza Development Holdings Limited 中 國 寶 沙 發 展 控 股 有 限 公 司 ） 2023 中期報告 目 錄 26 簡明綜合中期財務報表附註 1 中國健康科技集團控股有限公司 二零二三年中期報告 2 公司資料 4 管理層討論及分析 15 其他資料及公司管治 21 簡明綜合損益及其他全面收益表 22 簡明綜合財務狀況表 24 簡明綜合權益變動表 25 簡明綜合現金流量表 公司資料 董事 執行董事 凌鋒教授 （主席） 王義斌先生 （行政總裁） 李文軍先生 （於二零二三年十一月二十一日退任） 許慶女士 （於二零二三年十一月二十一日退任） 黎子彥先生 （於二零二三年十一月二十一日退任） 陳偉龍先生 （於二零二三年八月十四日自 獨立非執行董事調任執行董事 並於二零二四年一月二十九日辭任） 非執行董事 顧蘇通先生 （於二零二三年十一月二十一日退任） 獨立非執行董事 郭中隆先生 周穎楠先生 （於二零二三年八月十四日獲委任） 畢雪女士 （於二零二三年八月十四日獲委任） 劉兆祥 ...

Financial Performance - For the six months ended December 31, 2023, the company's revenue was RMB 19,020,000, a decrease of 17.3% compared to RMB 23,021,000 for the same period in 2022[4] - Gross profit for the same period was RMB 3,758,000, down 26.0% from RMB 5,069,000 in the previous year[4] - The company reported a significant debt restructuring gain of RMB 202,024,000, leading to a pre-tax profit of RMB 201,423,000 compared to a loss of RMB 1,244,000 in the prior period[4] - The net profit for the period was RMB 201,421,000, a substantial recovery from a loss of RMB 1,244,000 in the previous year[4] - The total comprehensive income for the period was RMB 207,869,000, compared to a loss of RMB 14,634,000 in the same period last year[4] - The total profit for the six months ended December 31, 2023, was RMB 5,233,000, compared to RMB 10,833,000 for the same period in 2022, reflecting a decline of 51.7%[21] - The company recorded a pre-tax profit of RMB 201,423,000 for the six months ended December 31, 2023, compared to a pre-tax loss of RMB 1,244,000 for the same period in 2022[21] - The company achieved a profit of approximately RMB 201,400,000 during the reporting period, a significant turnaround from a loss of approximately RMB 1,200,000 in the previous period[51] Assets and Liabilities - The company's current assets decreased to RMB 19,160,000 from RMB 22,621,000 as of June 30, 2023[5] - Current liabilities significantly decreased to RMB 14,582,000 from RMB 442,894,000, indicating improved liquidity[5] - The company's total assets less current liabilities stood at RMB 126,856,000, a recovery from a negative position of RMB 302,251,000[5] - Total assets as of December 31, 2023, amounted to RMB 141,438,000, an increase from RMB 140,643,000 as of June 30, 2023[22] - Total liabilities decreased to RMB 124,616,000 as of December 31, 2023, from RMB 457,351,000 as of June 30, 2023, indicating a significant reduction in debt[22] - As of December 31, 2023, the company had total assets valued at approximately RMB 141,400,000 and net assets of approximately RMB 16,800,000[52] - The capital debt ratio as of December 31, 2023, was approximately 88.1%, a significant improvement from 325.2% on June 30, 2023[56] Business Operations - Forestry business revenue was RMB 5,440,000, down 36.5% from RMB 8,580,000 in the same period last year, while ginseng business revenue was RMB 13,580,000, a decrease of 6.0% from RMB 14,441,000[21] - The company successfully obtained a logging permit for 12,044.0 cubic meters in December 2023, with sales of approximately 5,620 cubic meters generating revenue of about RMB 5,400,000 during the reporting period[39] - The ginseng business generated revenue of approximately RMB 13,600,000 during the reporting period, sourced from the purchase of ginseng from suppliers[40] - The company has initiated ginseng cultivation in its existing forests, with a first phase planting of approximately 6 million ginseng seeds on 59 acres[40] - The company owns a total of 117,424 acres (approximately 7,829 hectares) of forest land in Sichuan Province, China, primarily consisting of cypress trees[38] - The company has established a long-term supply framework agreement with suppliers to ensure a stable supply of ginseng[40] Employee and Governance - As of December 31, 2023, the group had 27 employees, an increase from 16 employees as of December 31, 2022[65] - Total employee costs during the reporting period amounted to approximately RMB 1,900,000, down from RMB 2,200,000 in the previous period[65] - The board did not recommend the payment of an interim dividend for the reporting period, consistent with the previous period[66] - The company has adopted all code provisions of the Corporate Governance Code and has been compliant, with some exceptions noted[70] - The Audit Committee, consisting of three independent non-executive directors, reviewed the company's interim and annual reports[72] - The company's interim financial statements for the reporting period were reviewed by the Audit Committee[73] - The board of directors includes both executive and independent non-executive members, ensuring a diverse governance structure[76] Corporate Changes - The company has undergone a restructuring process, with shares resuming trading on July 28, 2023, after fulfilling the listing rules[8] - The company completed a capital and debt restructuring on July 28, 2023, and its shares resumed trading on the same day[34][35] - The company changed its name from "China Bozza Development Holdings Limited" to "China Health Technology Group Holding Company Limited" effective November 27, 2023[64] - There were no significant events after the reporting period that could materially impact the company's operations and financial performance[63] - The company agreed to acquire a 52% stake in a target company for RMB 7,128,670, which will become a non-wholly owned subsidiary[59] Financial Management - The company incurred financing costs of RMB 51,000 for the six months ended December 31, 2023, down from RMB 8,967,000 in the previous year[23] - The company’s bank interest income was RMB 2,000 for the six months ended December 31, 2023, compared to RMB 3,000 for the same period in 2022[22] - Administrative expenses increased by 55.6% to approximately RMB 8,400,000 from about RMB 5,400,000 in the previous period, primarily due to legal and professional fees as well as depreciation[46] - The company recorded a debt restructuring gain of approximately RMB 202,020,000, resulting from the difference between the settled debt's book value of approximately RMB 410,170,000 and the amounts issued to creditors[48] - The company reported a net loss attributable to shareholders of RMB 201,421 thousand for the six months ended December 31, 2023, compared to a loss of RMB 1,244 thousand for the same period in 2022[31] - Trade receivables decreased from RMB 6,933 thousand as of June 30, 2023, to RMB 4,212 thousand as of December 31, 2023[14] - Trade payables decreased from RMB 99,008 thousand as of June 30, 2023, to RMB 10,840 thousand as of December 31, 2023[15] - The company recorded revenue of approximately RMB 19,000,000 during the reporting period, a decrease of 17.4% compared to RMB 23,000,000 in the previous period[43] - Gross profit for the reporting period was approximately RMB 3,800,000, down from RMB 5,100,000 in the previous period, reflecting a decline of 25.5%[44]

China Bozza Development Holdings Limited 中 國 寶 沙 發 展 控 股 有 限 公 司 (於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 (股 份 代 號 ：01069 ) 年 報 2023 ANNUAL REPORT 2023 (Stock Code: 01069) 司 China Bozza Development Holdings Limited (Incorporated in the Cayman Islands with limited liability) 中 國 寶 沙 發 展 控 股 有 限 公 China Bozza Development Holdings Limited 中國寶沙發展控股有限公司 Annual Report 2023 年報 ) China Bozza 2023 AR cover Size: 210 x 285 mm / Open Size: 437 x 285 mm / Spine width: 17 mm 目 錄 | 公司資料 | 2 | | --- | --- | | 財務概要 | 4 | | 管理層討論及分析 | ...

B_table indent_4.5 mm N_table indent_4 mm 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 中 國 寶 沙 發 展 控 股 有 限 公 司 China Bozza Development Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：1069） 截至二零二三年六月三十日止年度之 經審核業績公告 財務摘要 • 截至二零二三年六月三十日止年度（「二零二三財年」），持續經營業務收益 約為人民幣（「人民幣」）58,700,000元。 • 於二零二三財年，本公司擁有人應佔虧損約為人民幣10,800,000元（截至二 零二二年六月三十日止年度（「二零二二財年」）：虧損約人民幣18,900,000元）。 • 於二零二三財年，本公司擁有人應佔全面開支總額約為人民幣10,100,000元（二 零二二財年：人民幣29,300,000元）。 • 於 二 零 二 三 年 六 月 三 十 日，資 本 負 ...

目 錄 2 公司資料 4 管理層討論及分析 19 其他資料及公司管治 26 簡明綜合損益及其他全面收益表 28 簡明綜合財務狀況表 29 簡明綜合權益變動表 30 簡明綜合現金流量表 31 簡明綜合 中 期財務報表附註 公司資料 董 事 執行董事 凌鋒教授 （主席） 李文軍先生 （行政總裁） 王岳先生 許慶女士 （於二零二一年九月十三日獲委任） 黎子彥先生 （於二零二一年九月十三日獲委任） 吳國雄先生 （於二零二二年一月三十一日辭任） 彭健龍先生 （於二零二二年一月三十一日辭任） 非執行董事 顧蘇通先生 （ 於 二 零 二 零 年 十 二 月 十 五 日 獲委任） 王莉妮女士 （於 二 零 二 一 年 三 月 八 日 獲 委 任 及 於二零二二年六月一日辭任） 獨立非執行董事 劉兆祥先生 黃凱瑩女士 （於 二 零 二 二 年 六 月 三 十 日 獲 委 任） 王義斌先生 （於 二 零 二 二 年 六 月 三 十 日 獲 委 任） 郭中隆先生 （於 二 零 二 二 年 六 月 三 十 日 獲 委 任） 田光梅女士 （於二零二二年六月一日辭任） 謝國生博士 （於 二 零 二 二 年 一 月 三 十 一 日 辭 任 ...